KATE CHARRON: Open Payments
NPI 1801047337 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$930 in 49 payments from 9 companies in 2025. Trend: 2023 $1,040 · 2024 $797 · 2025 $930
Food & beverage: $930
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $377 |
| Madrigal Pharmaceuticals | 8 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $150 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $49 |
| Ardelyx, Inc. | 2 | $46 |
| Janssen Biotech, Inc. | 2 | $32 |
| Digestive Care, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Gilead Sciences, Inc. | 1 | $14 |
Products named: REZDIFFRA, LINZESS, CREON, ENTYVIO, RINVOQ, XIFAXAN, IBSRELA, VIBERZI.
Industry payments across CT — which companies pay providers there.
